Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...

Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access ...

Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 4-5 in opposition of a favorable benefit-risk profile for UGN-102 (mitomycin) intravesical solution in adult patients with recurrent low-grade ...

Key Takeaways The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant ...

In 2025, cytoreductive nephrectomy (CN) remains an integral part of the multidisciplinary management of metastatic renal cell carcinoma (mRCC). Rapid advances in systemic therapies—particularly immune ...

Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) is staged, graded, and treated according to risk stratification, with detailed explanations of low-, intermediate-, and high-risk ...

The real-world, phase 4 COMPOSUR study (NCT05067478) found that nearly 60% of patients taking vibegron remained on treatment at 1 year. 1 These data were presented at the 2025 American Urological ...

A panelist discusses how the outcomes of this study broadly align with real-world treatment patterns and clinical experiences, where enzalutamide and darolutamide both demonstrate efficacy in ...

A recent study examined the relationship between randomized controlled trials and real-world efficacy of prostate cancer treatments. 1 Investigators found that benefits of treatments that are observed ...

Panelists discuss how specific tumor characteristics, such as papillary architecture and presence of carcinoma in situ, guide risk-adapted treatment decisions in non–muscle-invasive bladder cancer.